A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards
Ultra-fast radiotherapy may spare healthy tissue while still killing tumours, but every centre is testing it differently. A coordinated programme would agree the measurements and run the trials that settle whether it works.
FLASH radiotherapy (dose delivered in under a second at ultra-high dose rate) shows a normal-tissue sparing effect in animals; the first human trial (FAST-01, proton FLASH for bone metastases) showed feasibility. Evidence is fragmented across manufacturers and centres with different beam types (electron, proton, photon prototypes), dose-rate definitions and dosimetry. The programme would fund a consortium to standardise dosimetry and dose-rate reporting, build a shared preclinical platform to define the biological conditions of the effect, and run coordinated multi-centre phase 2 and randomised trials in indications where normal-tissue toxicity limits cure (head and neck, thoracic, paediatric). Without coordination the field risks a decade of unconvincing small studies.
- Surgery and radiotherapy cure most, get least · Surgery and radiotherapy cure more people than drugs do, but attract a fraction of the research investment.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.
Pages like this
not linked directly; found by shared links- IdeaCompact FLASH and proton systems at the price of a conventional linac
Shares IBA (Ion Beam Applications), FLASH radiotherapy, Varian (Siemens Healthineers), Proton therapy.
- IdeaA national repository of radiotherapy dose plans linked to outcomes
Shares Varian (Siemens Healthineers), Proton therapy, Surgery and radiotherapy cure most, get least, Toxicity and quality of life are undervalued.
- PersonJürgen Debus
Shares A regulatory pathway for new radiotherapy techniques modelled on drug development, Pooled coverage-with-evidence for proton therapy across all centres, Proton therapy.
- IdeaCoverage-with-evidence registries for MR-guided and adaptive radiotherapy
Shares A regulatory pathway for new radiotherapy techniques modelled on drug development, Pooled coverage-with-evidence for proton therapy across all centres, Varian (Siemens Healthineers), Surgery and radiotherapy cure most, get least.
- TechnologyProton arc therapy
Shares IBA (Ion Beam Applications), Varian (Siemens Healthineers), Proton therapy.
- PersonMichael Baumann
Shares A regulatory pathway for new radiotherapy techniques modelled on drug development, Core-funded radiotherapy trials infrastructure with central quality assurance, Proton therapy.
- InstitutionAarhus University Hospital
Shares Varian (Siemens Healthineers), Proton therapy, Surgery and radiotherapy cure most, get least, Head and neck squamous cell carcinoma.
- InstitutionCentre Antoine Lacassagne
Shares IBA (Ion Beam Applications), Proton therapy, Head and neck squamous cell carcinoma.